Agoracom Blog Home

Archive for the ‘Featured’ Category

Tetra Bio-Pharma Announces Approval by Health Canada of its Phase I Trial of dried Cannabis $TBP.ca

Posted by AGORACOM-JC at 12:39 PM on Thursday, February 16th, 2017

Tbp large

  • Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis
  • We are very pleased to announce the authorization of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

OTTAWA, ONTARIO–(Feb. 16, 2017) - PhytoPain Pharma Inc. (PPP), a subsidiary of Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (CSE:TBP)(CSE:TBP.CN), a pharmaceutical company focused on developing and commercializing therapeutic cannabis-based products for the treatment of pain is pleased to announce that the Therapeutic Products Directorate (TPD) of Health Canada has approved its Phase I clinical study of smoked cannabis.

Tetra has worked with Algorithme Pharma, an Altasciences company, for the preparation of the Clinical Trial Application (CTA) for the conduct of a Double-Blind Phase I Study to Assess Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Multiple Daily Ascending Doses of Cannabis (Delta-9-tetrahydrocannabinol/ Cannabidiol) by Smoking/Inhalation in Healthy Male and Female Volunteers. The CTA was submitted to Health Canada and the research ethics review board in December 2016. On January 3, 2017, the clinical trial received approval from the Institutional Review Board. TPD issued a Letter of Authorization for the conduct of the Phase I clinical trial on February 16, 2017. Algorithme Pharma will be initiating the clinical trial activities in the coming weeks.

²We are very pleased to announce the authorisation of the Phase I clinical trial by TPD. This is an important milestone in the clinical development of smoked Cannabis in North America and we are proud to be working with Algorithme pharma, a Clinical Research Organization with many years of experience and expertise in the conduct of Phase I clinical studies,² said Dr. Chamberland, Chief Science Officer.

“This trial is part of Tetra’s commitment to develop medical Cannabis as a prescription drug for patients. The outcome of this trial is going to have significant implications in medical Cannabis research as it is a first pharmaceutical clinical trial assessing the effects of smoked Cannabis on cognitive function in healthy volunteers” said Mr. Rancourt, Chief Executive Officer

Earlier this month, Tetra and IntelGenx announced the co-development of Dronabinol AdVersa® Mucoadhesive controlled-release tablet for the management of Breakthrough Cancer Pain. The significant advantage of the Mucoadhesive technology was demonstrated in a Phase I clinical trial. The study demonstrated the delayed-release of THC avoids a rapid increase in the blood. ²With both of these products in clinical development, Tetra is on track with its objective to bring Cannabis-based prescription drugs to the market. Both of these products are promising alternatives in the battle for the reduction of opioids and improving quality of life in patients with chronic pain², added Dr. Chamberland.

The Canadian Securities Exchange (“CSE”) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Guy Chamberland
Chief Science Officer
(514) 220-9225

Lithium: The Fuel of the Green Revolution $DGO.ca $FMR.ca $SX.ca $BFF.ca $NAM.ca

Posted by AGORACOM-JC at 4:26 PM on Wednesday, February 15th, 2017

INTERVIEW: American Creek Discusses a Compelling Property Portfolio $AMK.ca

Posted by AGORACOM-JC at 8:42 AM on Thursday, February 2nd, 2017

Pacific North West Capital Announces Effective Date of Share Consolidation and Name Change $PFN.ca

Posted by AGORACOM-JC at 4:35 PM on Tuesday, January 31st, 2017

Hublogo1 copy

  • Received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc.
  • Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New Age Metals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”

Vancouver, British Columbia / January 31, 2017 - Pacific North West Capital Corp. (“PFN”) (TSXV: PFN OTCQB: PAWEF FSE: P7J) announces that further to news release of January 25, 2017, PFN has received approval to implement its proposed three (3) old for one (1) new share consolidation and name change to New Age Metals Inc. (the “Company”). Effective at the opening of the market on February 1, 2017 the common shares of Pacific North West Capital Corp. will be delisted and the post-consolidated shares of New AgeMetals Inc. will begin trading on the TSX Venture Exchange under its new trading symbol “NAM”.

Letters of transmittal will be sent to the registered shareholders providing instructions to surrender the share certificates evidencing their pre-consolidated common shares for replacement certificates of New Age Metals Inc. representing the number of post-consolidated common shares they are entitled to as a result of the consolidation. Until surrendered, each certificate representing the pre-consolidated common shares will be deemed to represent the number of post-consolidated common shares of New Age Metals Inc. that the holder thereof is entitled to as a result of the consolidation. The Company will not be issuing fractional shares as a result of the consolidation. Instead, all fractional shares equal or greater to one-half will be rounded to the next whole share.

The Company’s website, newagemetals.com, is currently under construction and is slated for completion in the upcoming days. During this transition period, please visit pfncapital.com for more information about the Company’s projects.

On behalf of the Board of Directors

“Harry Barr”

Harry G. Barr

Chairman and CEO

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Note Regarding Forward Looking Statements: This release contains forward-looking statements that involve risks and uncertainties. These statements may differ materially from actual future events or results and are based on current expectations or beliefs. For this purpose, statements of historical fact may be deemed to be forward-looking statements. In addition, forward-looking statements include statements in which the Company uses words such as “continue”, “efforts”, “expect”, “believe”, “anticipate”, “confident”, “intend”, “strategy”, “plan”, “will”, “estimate”, “project”, “goal”, “target”, “prospects”, “optimistic” or similar expressions. These statements by their nature involve risks and uncertainties, and actual results may differ materially depending on a variety of important factors, including, among others, the Company’s ability and continuation of efforts to timely and completely make available adequate current public information, additional or different regulatory and legal requirements and restrictions that may be imposed, and other factors as may be discussed in the documents filed by the Company on SEDAR (www.sedar.com), including the most recent reports that identify important risk factors that could cause actual results to differ from those contained in the forward-looking statements. The Company does not undertake any obligation to review or confirm analysts’ expectations or estimates or to release publicly any revisions to any forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. Investors should not place undue reliance on forward-looking statements.

INTERVIEW: American Creek Discusses the Invaluable addition of Jeff Kyba P.Geo to the Team $AMK.ca

Posted by AGORACOM-JC at 8:10 AM on Tuesday, January 31st, 2017

  • American Creek Resources is a precious metals exploration company with an impressive portfolio of high-potential gold and silver projects in British Columbia.  These include properties in B.C.’s prolific Golden Triangle, one of the richest areas of mineralization in the world.
  • MTJLS Mineralization in the Treaty Creek claims area lies within the same broad hydrothermal system that generated the several deposits on the Seabridge Gold KSM and the Pretivm Brucejack properties that lie immediately southwest of the Treaty Creek claims
  • So far over 130 million ounces of gold, 800 million ounces of silver and 20 billion pounds of copper (all categories included), representing one of the greatest concentrations of metal value on the planet, have been delineated within the geological system shared by KSM, Brucejack, and Treaty Creek.

Hub On AGORACOM / Corporate Profile / Watch Interview!

Namaste Announces Record Quarterly Revenue of over $2M for Q1 2017 $N.ca

Posted by AGORACOM-JC at 9:51 AM on Monday, January 30th, 2017

Nlogo

  • Recorded record quarterly revenue of $2,087,188, an increase of 77.6% from the first quarter of 2016;
  • Generated gross profit of $683,016, an increase of 75.9% from the first quarter of 2016;
  • Expanded the customer list to over 250,000 individuals producing monthly traffic of approximately 600,000 site visits in November

VANCOUVER, BRITISH COLUMBIA–(Jan. 30, 2017) - Namaste Technologies Inc. (“Namaste” or the “Company“) (CSE:N)(CSE:N.CN)(FRANKFURT:M5BQ) is pleased to announce the filing of its unaudited quarterly financial statements, management’s discussion and analysis, and certification of the quarterly filings for the first quarter of fiscal 2017. The statements for the period can be accessed on SEDAR at www.sedar.com.

The operational and financial highlights for the period include the following:

  • Recorded record quarterly revenue of $2,087,188, an increase of 77.6% from the first quarter of 2016;
  • Generated gross profit of $683,016, an increase of 75.9% from the first quarter of 2016;
  • Expanded the customer list to over 250,000 individuals producing monthly traffic of approximately 600,000 site visits in November;
  • Closed the acquisition of the assets of URT1 Limited, which comprised its Everyonedoesit business (“Everyonedoesit”) and raised approximately $3.5 million of capital; and
  • Appointed experienced members to the management team and board.

Financial Results

During the financial reporting period from September 1, 2016 to November 30, 2016, the Company focused efforts on further expanding its traffic and customer base, growing revenues, integrating the asset acquisitions of VaporSeller and Everyonedoesit, and securing capital to expand operations. Because of these focused initiatives, the Company achieved the following financial results:

  • Net revenue of $2,087,188 (Q1 2016 – $1,175,341), an increase of 77.6% as compared to the first quarter of 2016. These financial results include net revenues for a 44-day period from the Everyonedoesit asset acquisition, which produced revenue of $316,460. On a gross basis (prior to adjustments for refunds, discounts and charge backs), the revenues for the period were $2,460,738, an increase of $373,550 to net revenues. These adjustments are anticipated to normalize as the Company has now integrated the acquisition of VaporSeller and URT1, which is anticipated to result in a higher net revenue going forward.
  • Cost of sales of $1,404,172 (Q1 2016 – $787,008), which resulted in a gross profit of $683,016 (Q1 2016 – $388,333). As a percentage of sales, the gross margin was 32.7% compared to 33.0% in the first quarter of 2016. Going forward, the Company is optimizing its product mix to include higher margin glassware, private label products such as the Gurutm and related product accessories, products sourced from larger volume manufacturers, and driving higher average purchase prices from the VaporSeller and URT1 acquisitions.
  • Operating costs of $1,580,087 (Q1 2016 – $513,977), an increase of 207.4% as compared to the first quarter of 2016. This increase in operating costs includes non-cash and currency expenses of $71,416. These costs relate to share based compensation and foreign exchange movements in the Company’s source currencies including the British Pound and Euro. In addition, were non-recurring legal expenses of $175,000 related to the URT1 acquisition and financing. After adjusting for these numbers, management estimates total operating costs of $1,333,671 for the period. In addition to these expenditures, the Company has also incurred costs associated with positioning the business for scalability and the administration of its public listing.
  • Comprehensive loss of $(897,072) (Q1 2016 – $(125,644)). Going forward, management anticipates sales growth to strengthen from organic revenue generation and completed acquisitions, cost of sales to reduce due to higher volume purchases and optimization of the product portfolio, and operating costs to reduce as a result of normalized operations, which management anticipates to result in profitability and positive cash flow generation in fiscal 2017.

Management Commentary

Sean Dollinger, President and CEO of Namaste, comments: “The first quarter of 2017 represents substantial financial progress. In the first quarter, our team obtained these results while integrating multiple acquisitions and fulfilling orders during some of our most active months. Going forward, we continue to streamline operations, including optimizing our websites, human resources, and distribution networks, and believe our financial results will continue to reflect the value we have created for shareholders.”

About Namaste Technologies Inc.

Namaste Technologies Inc. is an emerging leader in vaporizer and accessories space. Namaste has 26 ecommerce retail stores in 20 countries, offers the largest range of brand name vaporizers products on the market and is actively manufacturing and launching multiple unique proprietary products for retail and wholesale distribution. The Company is currently focused on expanding its product offering, acquisitions and strategic partnerships, and entering new markets globally.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Direct: +1 (786) 389 9771

Email: info@namastevapes.com

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.com

www.namastevaporizers.co.uk

www.vaporseller.com

www.everyonedoesit.com

www.everyonedoesit.co.uk

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors 5 discussed in the Company’s disclosure documents which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
info@namastevapes.com
www.namastetechnologies.com

eSports: Facebook takes over from ESPN2 $GMBL

Posted by AGORACOM-JC at 3:08 PM on Thursday, January 26th, 2017
Arizona State's 2016 "Heroes of the Dorm" national championship computer gaming team during the final game.
  • “Facebook provides a great opportunity to offer this experience to new viewers around the globe and with a new level of engagement,” said Blizzard’s college eSports lead Adam Rosen. “We were very happy with the two years spent working with ESPN on the program and look forward to another great year with Facebook.”

Arizona State’s 2016 “Heroes of the Dorm” national championship computer gaming team… more

“Facebook provides a great opportunity to offer this experience to new viewers around the globe and with a new level of engagement,” said Blizzard’s college eSports lead Adam Rosen. “We were very happy with the two years spent working with ESPN on the program and look forward to another great year with Facebook.”

A Facebook spokesperson said the social media site will enable viewers to engage with each other around the world in real time in addition to providing statistics, team and player profiles.

Heroes of the Dorm is structured like the NCAA basketball season. The regular season, or group play, happens on the last two weekends of February and the first weekend of March. Regional competition takes place March 4-9 to narrow the field to 64 five-player teams, the same number as the NCAA tournament.

At that point teams are put into a single-elimination bracket that leads to the “Heroic Four” and national championship, both played on April 8.

College students have begun registering for this year’s competition, which was won in 2015 by UC Berkeley and last year by Arizona State. This year’s tournament includes $500,000 in scholarships and prizes.

Source: http://www.bizjournals.com/sanjose/news/2017/01/26/esports-new-deal-facebook-takes-over-from-espn2.html

American Creek Announces That JV Partner Tudor Gold Has Retained Jeff Kyba, P. Geo. $AMK.ca

Posted by AGORACOM-JC at 9:14 AM on Tuesday, January 24th, 2017

Hublogolarge2 copy

  • Retained the services of Mr. Jeff Kyba, P. Geo., to provide advice and direction on the exploration and development of Tudor’s mineral claims in the “Golden Triangle” near Stewart, British Columbia
  • Brings a wealth of personal knowledge about the mineralization and potential of this geologically rich area. 

CARDSTON, ALBERTA–( Jan. 24, 2017) - American Creek Resources Ltd. (TSX VENTURE:AMK) (“American Creek”) is pleased to report that Tudor Gold Corp. (“Tudor”) has retained the services of Mr. Jeff Kyba, P. Geo., to provide advice and direction on the exploration and development of Tudor’s mineral claims in the “Golden Triangle” near Stewart, British Columbia.

Mr. Kyba has worked with both the British Columbia Geological Survey and the British Columbia Ministry of Mines as the Regional Geologist for the Skeena Mining District, BC’s busiest district which includes the “Golden Triangle”. He brings a wealth of personal knowledge about the mineralization and potential of this geologically rich area.

Mr. Kyba is best known for his work with the British Columbia Geological Survey where, together with a fellow geologist, he carried out one of the most important and influential studies of the geology of the “Golden Triangle”. That study resulted in the publishing of the foremost report on the Treaty Glacier south to Stewart portion of the “Golden Triangle” titled Structural and stratigraphic control of porphyry and related mineralization in the Treaty Glacier – KSM – Brucejack – Stewart trend of western Stikinia. They formed the opinion that this trend, which encompasses both Tudor/American Creek joint ventures, the Treaty Creek and Electrum projects, “is one of the most productive and promising in northwestern British Columbia.”

Walter Storm, President and CEO of Tudor Gold, stated: “We see it as a great advantage to have Mr. Kyba involved in our exploration program. At Tudor Gold we rely on the best people and the most technologically advanced exploration methods we can employ. Mr. Kyba will fit right in.”

Darren Blaney, American Creek CEO stated: “We are thrilled with this new development of Mr. Kyba now being involved in advancing our joint venture projects with Tudor. We have referenced his geological study work several times in the past. To now have him personally join in the effort adds both credibility and significant further discovery potential to our projects. We are very much looking forward to the upcoming 2017 exploration programs.”

Information relating to the Corporation is available on its website at www.americancreek.com.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

American Creek Resources Ltd.
Kelvin Burton
403 752-4040
info@americancreek.com
www.americancreek.com

U of T announces creation of new esports scholarship, Dallas Cowboys considering enterance to Esports World $GMBL

Posted by AGORACOM-JC at 9:24 AM on Monday, January 23rd, 2017

University of Toronto announces creation of new esports scholarship

by
  • University of Toronto has founded Canada’s first university-specific esports scholarship
  • Will be funded by alumnus and global equities investor Victor Xin
  • Victor Xin Scholarship in esports will be awarded to one full-time undergraduate student in Applied Science & Engineering with at least a 3.5 GPA, who has a “passion for esports or gaming”

Jphillips23 / Wikimedia Commons
The University of Toronto has founded Canada’s first university-specific esports scholarship. It will be funded by alumnus and global equities investor Victor Xin.The Victor Xin Scholarship in esports will be awarded to one full-time undergraduate student in Applied Science & Engineering with at least a 3.5 GPA, who has a “passion for esports or gaming” and participates in the UofT esports club. U of T does not specify how much the scholarship is worth, but does note that the first scholarship will not be awarded until fall 2018.“There are trailblazers on campus who are rallying a different set of students to build campus organizations focused on an alternative way of learning to lead and succeed in life,” Xin said in a press release. “Society may not recognize them yet – but we shouldn’t let them fall through the cracks.”According to a press release, Xin played StarCraft while he was in the Engineering program in 2008 and started the U of T esports Club. He now mostly plays Dota 2 when he has the time.U of T joins a growing list of universities and colleges that have begun to offer esports scholarships. In 2016, the University of California at Irvine launched a scholarship program, while Robert Morris University and the University of Pikeville both kicked off esports scholarship programs in 2015.

Tetra BioPharma Enters into a Clinical Research Partnership with Sante Cannabis, Quebec’s Leading Medical Cannabis Institution $TBP.ca

Posted by AGORACOM-JC at 9:10 AM on Monday, January 23rd, 2017

Tbp large

  • Entered into a clinical research partnership with Santé Cannabis
  • Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration
  • Ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication

OTTAWA, ONTARIO–(Jan. 23, 2017) - PhytoPain Pharma Inc. (“PPP“), a subsidiary of Tetra Bio-Pharma Inc. (“TetraBio” or the “Company” or “TBP“) (CSE:TBP)(CSE:TBP.CN) is pleased to announce that it has entered into a clinical research partnership with Santé Cannabis. Under the partnership, Santé Cannabis will be working with PPP to develop the late phase clinical trial protocols that will be used to obtain substantial evidence of the safety and efficacy of PPP001 required for a new prescription drug approval from Health Canada and the USA Food and Drug Administration (“FDA“). These ground-breaking trials seek to receive the first approval for a Canadian-manufactured cannabis-based prescription medication.

Santé Cannabis is a private clinic specialized in the clinical application of medical cannabis for the treatment of pain and other chronic and terminal health conditions. The clinic’s team of physicians and support staff has unparalleled experience in the assessment and monitoring of medical cannabis patients. Santé Cannabis is the leading medical cannabis research institute in the province of Québec and the primary recruitment site for the province-wide Quebec Cannabis Registry. “Our clinic has provided services to almost 2,000 patients referred by over 1,500 physicians across Québec,” states Erin Prosk, Director of Santé Cannabis. “It is clear that both the medical community and the Quebec patient population are in desperate need of information about the potential benefits and risks of medical cannabis treatments. The status of medical cannabis as an unapproved treatment dissuades many physicians from writing a prescription and requires patients to pay for treatments out of pocket. Of the 2,000 patients that we have seen, there is not one who is not burdened by this financial barrier.”

Dr. Antonio A.L. Vigano, MD, MSc, will lead the Santé Cannabis team to administer the Phase II-III clinical trials in close collaboration with Dr. Irina Kudrina, MDCM, CCFP, CSP, and Santé Cannabis Medical Director Dr. Michael Dworkind, MD, CCFP, FCFP. Dr. Vigano is an attending physician in the Supportive and Palliative Care Service at the McGill University Health Centre and an Associate Professor in the McGill University Department of Oncology. He is the Director of the McGill Nutrition and Performance Laboratory and the Cancer Rehabilitation (CARE) Program. Dr. Vigano has assessed and followed approximately 400 patients during his 18-month tenure at Santé Cannabis. “It has become clear that medical cannabis can be a critical complementary therapy for the treatment of pain,” states Dr. Vigano. “Administering these late phase clinical trials is necessary to rigorously validate the efficacy and tolerability that I observe every day with my patients at Santé Cannabis. If specific medical cannabis products and protocols such as that we will design for PPP001 can withstand the pharmaceutical approval process, it cannot be denied as a valid pain therapy. Cost-coverage should be a logical next step.”

Dr. Irina Kudrina is a McGill-certified pain physician and an attending physician and head of the chronic pain services at the Queen Elizabeth GMF-U and Assistant professor and clinician-researcher at the McGill University Department of Family Medicine. “At present, medical cannabis has already become an important medicine in the fields of oncology, chronic pain, neurology and others. In a clinical review* published in Journal of the American Medical Association (2015), Harvard-based researchers highlighted its use in some medical conditions as being supported by high quality evidence. In Canada, the efforts by regulatory, medical, and pharmaceutical bodies and by the patient advocacy movements have been targeting multiple structural, legal and information barriers still prevailing from the times when long-term high dose opioid therapy was prescribed to chronic pain patients despite its chronic toxicity effects and without high quality evidence for such use. While the clinical use of medical cannabis remains a stigmatized and poorly researched option for some medical conditions, sufficiently large-scale late-phase clinical trials on efficacy, safety and tolerability of medical cannabis are long overdue. These studies might open the door for another class of medications in an attempt to fill the current significant gap for more long-term pharmacological options.”

*(https://www.ncbi.nlm.nih.gov/pubmed/26103031)

PPP entered into this partnership because of Santé Cannabis’ unique expertise and dedication to a pharmacovigilance approach in medicine. The clinic has established clinical practices that help minimize adverse effects in patients and will help design the treatment protocols for the Phase II-III studies. According to Dr. Guy Chamberland, Chief Scientific Officer and Regulatory Affairs, “Adequately designing a late phase clinical trial for the evaluation of the safety and efficacy of inhaled Cannabis requires clinical teams experienced in handling the administration of Cannabis by inhalation to patients. The medical experts of Santé Cannabis complement the scientific and medical experts of our Clinical Advisory Board and provide PPP with an exceptionally solid foundation for the clinical development of Cannabis products as prescription drugs.”

Once authorized by Health Canada, Santé Cannabis will be recruiting participating physicians and patients from the Montreal area throughout 2017. For more information, please contact the clinic by email at info@santecannabis.ca.

About Santé Cannabis:

Santé Cannabis is Québec’s only medical clinic and resource centre dedicated to the clinical practice and research of medical cannabis treatments. Since opening in November of 2014, physicians at Santé Cannabis have assessed almost 2,000 patients referred by more than 1,500 physicians across the province of Québec. Santé Cannabis currently administers several clinical study protocols, including the Québec Cannabis Registry in collaboration with the Research Institute of the McGill University Health Centre and in accordance with the regulations of the Collège des Médecins du Québec.

The Canadian Securities Exchange (CSE) has not reviewed this news release and does not accept responsibility for its adequacy or accuracy.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a licence for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Chief Executive Officer
(613) 421-8402

Tetra Bio-Pharma Inc.
Ryan Brown
VP Business Development and Communications
(613) 421-8402

Tetra Bio-Pharma Inc.
Andre Audet
Executive Chairman
(613) 421-8402